Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2014-03-20 · Food and Drug Administration, HHS · Rules and Regulations

Rules and Regulations. Notification of withdrawal of approval

354 words·~2 min read·/register/2014/03/20/2014-05883·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Agency: Food and Drug Administration, HHS
Action: Notification of withdrawal of approval
Citation: FR Doc. 2014-05883 · Docket No. FDA-2014-N-0002 · 21 CFR 558

Summary

The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) and two abbreviated new animal drug applications (ANADAs) for three-way, fixed-ratio combination drug Type A medicated articles containing chlortetracycline, sulfathiazole, and penicillin. This action is being taken at the sponsor's request because these products are no longer manufactured or marketed.

Dates

Withdrawal of approval is effective March 31, 2014.

Supplementary Information

Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 has requested that FDA withdraw approval of the following NADA and two ANADAs because the products are no longer manufactured or marketed: NADA/ANADA Proprietary name 039-077 CSP 250 (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article. 200-140 AUREOZOL (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article. 200-167 AUREOZOL 500 Granular (chlortetracycline, sulfathiazole, and penicillin) Type A medicated article. The NADAs listed were identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209”, December 2013. Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADA 039-077, ANADA 200-140, and ANADA 200-167, and all supplements and amendments thereto, is hereby withdrawn, effective March 31, 2014. Elsewhere in this issue of the Federal Register , FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications. Dated: March 12, 2014. Bernadette Dunham, Director, Center for Veterinary Medicine. [FR Doc. 2014-05883 Filed 3-19-14; 8:45 am]

Connectionstraces to 1
1 reference not yet in our index
  • 21 CFR 558
Citation graph
cites case law
Rules and Regulations
Notification of withdrawal of approval
Cite21 CFR 558
Cites 2Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.